Whitney Marie Starr, MS, FNP
Clinical Education Coordinator, Mountain Plains AETC
Assistant Professor, Division of Infectious Diseases, School of Medicine
University of Colorado Denver

Steven Johnson, MD
Medical Director, Mountain Plains AETC
Professor of Medicine, Division of Infectious Diseases, School of Medicine
University of Colorado Denver

REVIEWER AND EDITOR:
Lucy Bradley-Springer, PhD, ACRN, FAAN
Principal Investigator and Director, Mountain Plains AETC
Associate Professor, Division of Infectious Diseases, School of Medicine
University of Colorado Denver
This guide is intended to help clinicians initiate care for HIV-infected patients. As with other chronic conditions, it is important that people living with HIV (PLWH) be seen on an on-going basis and at regular intervals. The first visit provides a critical opportunity to establish rapport for a productive health-care relationship. This guide lays the groundwork for continuing care, provides a succinct description of the initial history and physical, and lists easily accessible resources.

In addition, we have provided two sample flow sheets that can be used to document care for your HIV-infected patients. The recommendations provided in the health maintenance flow sheets are based on information from currently available guidelines. Please consult the resources at the end of this publication for the most up to date information. The sample flow sheets may be copied or modified for your personal or clinic use.

**CHIEF COMPLAINT**

Initial visits often occur after a patient has received a positive HIV test. Initial visits may also occur if a patient could have been exposed to HIV, has been determined to have risk factors for acquiring HIV infection, or has symptoms that could indicate HIV infection. Some patients may have been treated for HIV at another facility and are transferring care to your practice as a result of changes in life circumstances, insurance coverage, or relocation.

**ASSESS HISTORY**

**History of Present Illness**

- Inquire about date of first diagnosis and circumstances that lead to testing (i.e., why the patient received an HIV test).
- If this is a new diagnosis:
  - Ask about previous testing.
  - Ask about any signs or symptoms of a flu-like illness that may have occurred between the last negative HIV test and the first positive HIV test.
  - A recent flu-like illness may be suggestive of acute HIV infection. If you suspect recent infection, consultation with an HIV expert is recommended as some patients may benefit from treatment with antiretroviral therapy (ART) during acute HIV infection.
  - Inquire about risk factors for acquiring HIV (e.g., sexual contact, intravenous drug use, blood transfusion).
  - Evaluate acute symptoms, if present.
• If this is a patient with a known history of HIV:
  ▪ Obtain date of first diagnosis
  ▪ Inquire about HIV treatment history
• Ask about all antiretroviral medications, including dates of use, reasons for discontinuation (e.g., side effects, drug resistance, poor adherence).
• Some patients only recognize medications by size and color. It is helpful to have a picture chart of medications available to ensure accurate identification.
• Include a history of immune function (lowest CD4+ T cell count) and most recent CD4+ T cell count and HIV viral load, if known.
  ▪ Inquire about risk factors for acquiring HIV (e.g., sexual contact, intravenous drug use, blood transfusion).
  ▪ Ask about opportunistic infections and other HIV-associated conditions.
  ▪ Find out where previous care was provided and when the patient was last seen for HIV care. Ask if records can be obtained.
  ▪ Evaluate acute symptoms, if present.
• For all patients, find out who knows about the patient’s HIV diagnosis and assess support systems and personal coping mechanisms.

**Past Medical History. Ask about:**
• other chronic medical conditions (e.g., diabetes, heart disease, high cholesterol)
• other sexually transmitted infections (e.g., herpes, genital warts, syphilis, gonorrhea)
• history of tuberculosis, tuberculosis testing, or exposure
• hepatitis history (known infection with hepatitis A, B, or C, or prior immunization to hepatitis A, B)
• hospitalizations
• surgeries
• mental health and substance use treatment history
• for women, obtain a gynecological history including:
  ▪ date of last Pap smear
  ▪ history of abnormal Pap smears
  ▪ pregnancy history
  ▪ last menstrual period, any irregular periods
  ▪ current method(s) of contraception, if applicable
**Immunization History.** Document vaccination dates, including tetanus, diphtheria, pertussis, influenza (annually), pneumococcal, polio, measles, mumps, rubella, HPV, and hepatitis A and B, or evidence of immunity.

**Medications.** Review use of all current medications, including:
- antiretroviral medications
- medications to prevent or treat opportunistic infections
- medications for conditions other than HIV infection (e.g., diabetes, cardiovascular disease, hyperlipidemia, pain)
- over-the-counter medications
- herbs, alternative medications, and/or nutritional supplements
- “as needed” and occasional prescription or over-the-counter medicines

**Allergies.**
- document allergic reactions to any medications
- document allergies to food and other environmental triggers

**Health Maintenance. Ask about previous:**
- primary care
- dental care, eye care, and other specialty care
- cholesterol screening
- cervical cancer screening
- anal cancer screening (anal pap)
- age- and sex-appropriate preventative health screenings such as:
  - colon cancer screening
  - mammography
  - prostate cancer screening

**Personal Social History.** Start with less threatening areas to establish communication and build rapport. Inquire about:
- employment (financial resources)
- housing (stability, safety of neighborhood)
- living arrangements (who lives with the patient) and social support
- pets (establish risk for infections such as toxoplasmosis)
- responsibilities (children, other relatives, partners)
- travel (especially to areas of endemic disease inside and outside of the United States)
• alcohol and tobacco use
• other substance use
  □ “Do you now or have you ever used drugs that weren’t available over the counter or prescribed by a health care provider?”
  □ “How do/did you use those drugs (i.e., inject, smoke, snort)?”
  □ “Do/did you share your drug-using equipment with others?”
• sexual activity
  □ “Are you sexually active?”
  □ “In your life, have you had sex with men, women, or both?”
  □ “How do you protect yourself and your partner(s) from sexually transmitted infections?”
• inquire about history of violence, including forced sex and domestic abuse

REVIEW OF SYSTEMS

• Constitutional: fevers, chills, night sweats, weight change, anorexia, fatigue
• HEENT: visual symptoms, hearing changes, sinus pain, oral lesions, sore throat, pain when swallowing
• Lymphatics: swollen or painful lymph nodes
• Cardiovascular: chest pain, palpitations
• Respiratory: shortness of breath, cough, sputum production
• Gastrointestinal: nausea, vomiting, diarrhea, abdominal pain
• Genitourinary: dysuria, frequency, urgency, hematuria
• Genital-rectal: sores, lesions, discharge, tenderness, rectal bleeding
• Neurologic: headaches, numbness or tingling in extremities
• Skin: rashes, sores
• Psychological: anxiety, depression, cognitive changes

PHYSICAL ASSESSMENT – a comprehensive physical exam:

• Constitutional: evaluate overall appearance
• HEENT: perform thorough oral, eye, and ear exams
• Lymphatic: evaluate for lymph node enlargement
• Heart: assess rhythm and rate, note presence of murmurs or rubs
• Lungs: assess breath sounds
• Abdomen: measure liver span, note any mass or organ enlargement
• Neurologic: test reflexes and sensations in lower extremities, assess mental status, cranial nerves
• Skin: note any rashes or lesions, evidence of trauma
• Musculoskeletal: tenderness, edema, limited range of motion
• Psychiatric: mood, judgment, ability to communicate
• Women: pelvic exam, anorectal exam, breast exam
• Men: genitourinary exam, anorectal exam, prostate exam

Note: depending on time, prioritization of needs, and patient comfort, GU and rectal exams may be deferred at the first visit, but should be done as soon as possible on all patients.

LABORATORY TESTING

• HIV antibody or 4th generation HIV antibody/antigen testing should be done to confirm infection unless patient produces reliable documentation.
• HIV plasma RNA level (HIV viral load).
• CD4+ T cell count (absolute and percentage).
• Complete blood count (CBC) with differential.
• Comprehensive metabolic panel (including liver enzymes, creatinine, and glucose)
• HIV resistance assay: Genotype testing should be performed for newly infected and treatment naïve patients.
• HIV resistance testing, including for Integrase Strand Transfer Inhibitor (INSTI) susceptibility, if applicable, should also be performed in patients with viremia on presentation who are currently on ART. Consider phenotype testing in addition for patients with known drug resistance.
• Hepatitis serologies: HAV Ab, HBsAb, HBcAb, HBsAg, HCV Ab.
• STD testing: including gonorrhea, chlamydia, syphilis in both men and women, and trichomoniasis in women at baseline. Site-specific testing (i.e., anus, urine, throat, and vagina) should be based on reported sexual practices and any history of site-specific symptoms.
• Baseline lipid profile and fasting glucose.
• Toxoplasma serology.
• Urinalysis and baseline creatinine clearance.
• PPD or interferon gamma release assay.
ADDITIONAL LABORATORY TESTING

Depending on the clinical situation, some clinicians recommend additional testing to include:

- **HLA-B*5701**: the presence of HLA-B*5701 is associated with a hypersensitivity reaction to abacavir. If present, abacavir should be listed as an ALLERGY and the patient should NOT be prescribed abacavir.
- **Co-receptor tropism assay**, if use of CCR5 antagonist is a consideration in the treatment regimen.
- **Glucose-6-Phosphate Dehydrogenase (g6pd)** prior to starting treatment with an oxidant drug such as dapsone or trimethoprim-sulfamethoxazole, in at-risk racial and ethnic populations. For example, people of Mediterranean, Asian, or African descent are more likely to have this result.
- **CMV IgG**, screen for latent infection in patients who are not men who have sex with men (MSM) or who have a history of injection drug use.
- **Chest x-ray** if warranted by symptoms or to rule out evidence of active tuberculosis infection if initial tuberculosis screening is positive.
- **Cryptococcal antigen and acid-fast bacilli blood cultures** in patients at risk for cryptococcal infection or disseminated Mycobacterium avium complex infection, CD4 ≤ 50 cells/mm³.
- **Pregnancy testing in all women of child-bearing age**

**To be addressed during visit:**

- Stage of HIV disease
- Medical indication and readiness for ART, or adherence to and appropriateness of current regimen if on ART
- Prior ART exposure or intolerance, possible resistance
- Medication interactions and adverse effects
- Other medical conditions
- Possible opportunistic infections
- Need for prophylaxis against opportunistic infections
- Prevention of transmission to others
- Family planning and contraception options for women of childbearing age
Health Maintenance, including:
- Immunizations
- TB testing
- Pelvic exam with cervical pap smear
- Anorectal exam with or without anal pap smear
- Age-appropriate health and wellness preventative health exams

Education, Discuss:
- HIV pathophysiology, including significance of HIV viral load and CD4+ T cell count, and the expected progression of disease of both treated and untreated HIV infection
- Routine lab tests with expected monitoring intervals
- Plan of care including need for immunizations and routine health maintenance
- The importance of adherence to ART
- The importance of staying in care and keeping appointments
- HIV transmission and methods to decrease risks to partners
- Community programs and social service needs

FOLLOW UP
- Schedule appointment to return to clinic.
- Explain how to contact providers between appointments, if needed.
- Review signs and symptoms to report between scheduled care visits.
- Refer to case manager for other services, including insurance and medication assistance, or other social service needs.
- Patients who achieve an undetectable viral load and are stable on ART for at least 24 months who are clinically stable may consider moving to every 6 month follow-up visits.
Sample Flow Sheet  
For Tracking  
Laboratory Results and Medication Lists

<table>
<thead>
<tr>
<th>Name: ____________________________</th>
<th>Date of Birth: ____________________________</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical Record #: ____________________________</td>
<td>Telephone: ____________________________</td>
</tr>
<tr>
<td>Pharmacy: ____________________________</td>
<td>Pharmacy #: ____________________________</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CD4+ T Cell Count (cells/mm³)</th>
<th>Date</th>
<th>Date</th>
<th>Date</th>
<th>Date</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD4+ T Cell Percentage (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIV viral load (copies/ml)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Medications**

<table>
<thead>
<tr>
<th>Name</th>
<th>Dose</th>
<th>Route</th>
<th>Frequency</th>
<th>Indication</th>
<th>Start Date</th>
<th>Stop Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Allergies:**

- ____________________________________________________________________________

**Prophylaxis**

<table>
<thead>
<tr>
<th>Indication</th>
<th>Medication Name(s)</th>
</tr>
</thead>
</table>
| *Pneumocystis jiroveci* pneumonia (PCP)  
  Absolute CD4 < 200 cells/mm³ or  
  CD4 %<14 |                        |
| *Mycobacterium avium* Complex (MAC)  
  Absolute CD4 < 50 cells/mm³ |                        |
| *Toxoplasmosis*  
  + IgG, Absolute CD4 < 100 cells/mm³ |                        |
### Immunizations

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Timeframe</th>
<th>Date</th>
<th>Date</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haemophilus influenzae type B vaccine</td>
<td>Administer to asplenic patients</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis A</td>
<td>2 doses: 0 and 6-12 months apart, document titer 1-2 months after last dose</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis B</td>
<td>3 doses: 0, 1 and 6 months apart, document titer 1-2 months after last dose</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HPV (HPV2 or HPV4 for women, HPV4 for men)</td>
<td>3 doses, 0, 8-12 weeks, and 24 weeks, up to age 26</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Influenza (NOT LAIV)</td>
<td>Annually</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumococcal (PPSV23)</td>
<td>2 doses 5 years apart and at age 65</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumococcal (PCV13)</td>
<td>Vaccinate with single dose of PCV 13 initially, followed by PPSV23 at least 8 weeks after. PCV13 should be given at least 1 year after PPV23 if previously vaccinated with PPV23.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Polio</td>
<td>Give 3 doses of IPV over 6-12 months if indicated (travel to endemic area)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Td/Tdap vaccine</td>
<td>Every 10 years; one dose of Td should be substituted for Tdap in adult patients</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Varicella vaccine</td>
<td>2 doses, 3 months apart in patients who do not have evidence of immunity, CD4+T cells ≥ 200 cells/mm³</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zoster vaccine</td>
<td>Once at age 60, if CD4+T cells ≥ 200 cells/mm³</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: Clinicians are encouraged to consult the references contained in the bibliography for the most up-to-date and appropriate health maintenance recommendations for their clinic population.
## Sample Flow Sheets
### For Tracking Adult Health Maintenance

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Timeframe</th>
<th>Date</th>
<th>Date</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antiretroviral therapy (ART)</td>
<td>Offer to all patients</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lipid Screen</td>
<td>Before initiation of ART, and 1-3 months after initiation of ART.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fasting Glucose and/or</td>
<td>Before initiation of ART, and 1-3 months after initiation of ART.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>hemoglobin A1c</td>
<td>Goal of &lt;7%, monitored every 6 months.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GC/Chlamydia screen</td>
<td>Once a year/site, and more frequently based on risk Repeat at 3 months</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>with positive result.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis B screen</td>
<td>Once, repeat based on risk</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis C screen</td>
<td>Once, repeat based on risk</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MAC prophylaxis</td>
<td>CD4+T cells &lt; 50 cells/mm³</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCP prophylaxis</td>
<td>CD4+T cells &lt; 200 cells/mm³</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Syphilis screen</td>
<td>Annually, repeat based on risk</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Toxoplasma screen</td>
<td>Once</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tuberculosis testing</td>
<td>Every 2 years, and with exposures</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parameter</td>
<td>Timeframe</td>
<td>Date</td>
<td>Date</td>
<td>Date</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>------</td>
<td>------</td>
<td>------</td>
</tr>
<tr>
<td>Anogenital exam</td>
<td>Annually in men and women</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trichomoniasis screening</td>
<td>All women; repeat at 3 months to ensure resolution of infection</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cervical Pap smear</td>
<td>Every 6 months, then annually after 2 consecutive negative Pap smears for women ages 21-65</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Family Planning</td>
<td>To be reviewed regularly with every woman of childbearing age, and to be screened at regular intervals with men.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Breast cancer screen</td>
<td>Annually in women ages &gt; 40; earlier if high risk</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colon Cancer Screening</td>
<td>Ages 50-75 colonoscopy every 10 years; if high risk, consider earlier May also consider Fecal Occult Blood annually, or flex sig every 5 years with FOB every 3 years</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dental exam</td>
<td>Every 6 months</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depression Screen</td>
<td>As needed, with support plan in place</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prostate Specific Antigen (PSA)</td>
<td>Weigh benefits and risks of screening: may begin at age 45 for African American men or men with family history of prostate cancer before the age of 65 Not recommended for men over the age of 70</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bone densitometry (DXA)</td>
<td>Postmenopausal women and men ≥ age 50</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lung cancer screening</td>
<td>Annually with low dose chest CT in 55-80 year old men and women with 30 year smoking history (USPSTF Grade B recommendation)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Cardiovascular prevention and use of ASA | Women: ages 55-79  
Men: ages 45-79  
ASA dose of 75-162 mg/day when benefits outweighs risks of GI hemorrhage |      |      |      |


